<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02400437</url>
  </required_header>
  <id_info>
    <org_study_id>14-559</org_study_id>
    <nct_id>NCT02400437</nct_id>
  </id_info>
  <brief_title>Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia</brief_title>
  <official_title>Phase II Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is evaluating a drug called ixazomib (also known as MLN9708) in&#xD;
      combination with dexamethasone and rituximab (the regimen is called IDR) as a possible&#xD;
      treatment for Waldenstrom's Macroglobulinemia (WM).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This research study is a Phase II clinical trial. Phase II clinical trials test the safety&#xD;
      and effectiveness of an investigational regimen, IDR, to learn whether IDR works in treating&#xD;
      a specific cancer. &quot;Investigational&quot; means that IDR is still being studied and that research&#xD;
      doctors are trying to find out more about it-such as the safest dose to use, the side effects&#xD;
      it may cause, and if IDR is effective for treating different types of cancer. It also means&#xD;
      that the FDA (the U.S. Food and Drug Administration) has not yet approved IDR for use in&#xD;
      participants with your type of cancer.&#xD;
&#xD;
      Ixazomib is a drug that may kill or stop cancer cells from growing by blocking the proteasome&#xD;
      within the cell, which is responsible for degrading or breaking down a variety of proteins.&#xD;
      This type of drug is called a proteasome inhibitor.&#xD;
&#xD;
      Rituximab is a type of protein called an antibody that attacks the cluster of differentiation&#xD;
      20 (CD20), a protein found on B-cells like WM. Rituximab is approved by the FDA for treating&#xD;
      non-Hodgkin lymphoma (NHL). Dexamethasone is a steroid and is similar to the hormones&#xD;
      naturally produced by the adrenal glands; it prevents the release of substances that cause&#xD;
      inflammation. Rituximab and dexamethasone are often used to treat WM, alone or in combination&#xD;
      with other drugs. Combinations with rituximab, dexamethasone and other proteasome inhibitors&#xD;
      have shown good response rates in WM participants. Ixazomib is a proteasome inhibitor; thus&#xD;
      the investigator swill investigate if the combination of Ixazomib, Rituximab, and&#xD;
      Dexamethasone is also active in WM.&#xD;
&#xD;
      In this research study, the investigators are combining a new treatment ixazomib with a&#xD;
      standard regimen, rituximab and dexamethasone, to determine whether this combination (IDR) is&#xD;
      effective and safe for participants with previously untreated WM.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">November 2019</completion_date>
  <primary_completion_date type="Actual">November 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Very Good Partial Response Rate (VGPR) for IDR</measure>
    <time_frame>76 weeks</time_frame>
    <description>Rate of very good partial response or better in patients treated with IDR. VGPR is defined as a &gt;90% reduction in serum IgM levels from baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>2 Years</time_frame>
    <description>Overall response includes the rate of complete response (CR), partial response (PR), minimal response (MR), stabl disease (SD) and progressive disease (PD). Minor response is &gt;25%-50% reduction in serum IgM from baseline. Partial Response is (&gt;50-90% reduction in serum IgM from baseline. Very Good Partial Response is &gt;90% reduction in serum IgM from baseline. Complete Response is resolution of all symptoms, normalization of serum IgM with disappearance of IgM paraprotein, resolution of any adenopathy or splenomegaly.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>From start of treatment to time of disease progression, assessed up to 4 years after treatment start</time_frame>
    <description>Duration of time from start of treatment to disease progression. Progressive disease is defined as occurring when a &gt;25% increase in serum IgM and an absolute 500mg/dL increase in IgM level occurs from the lowest attained response value, or progression of clinically significant disease related symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate by MYD88 L265P and CXCR4-WHIM Status</measure>
    <time_frame>2 Years</time_frame>
    <description>To evaluate the overall response rate of participants by MYD88 L265P and CXCR4-WHIM mutations in WM. Overall response is defined as achieving at least a minor response, or &gt;25% reduction in serum IgM from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (TTP)</measure>
    <time_frame>From start of treatment to time of disease progression, assessed up to 4 years after treatment start</time_frame>
    <description>Duration of time from start of treatment to time of disease progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>From the time each participant achieved a response to time of disease progression, assessed up to 4 years after treatment start</time_frame>
    <description>The duration of response is measured from the time a participant achieved a response until the date of progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Next Therapy (TTNT)</measure>
    <time_frame>From start of treatment until the participant begins a new therapy, assessed up to 4 years after treatment start</time_frame>
    <description>Duration from start of protocol treatment to time of initiation of new therapy.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Waldenstrom's Macroglobulinemia</condition>
  <arm_group>
    <arm_group_label>IDR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>- IDR The study treatment will consist on an induction and a maintenance phase. Dose modification will be permitted for toxicity&#xD;
Induction cycles will be 4 weeks long, Maintenance cycles 8 weeks long.&#xD;
Ixazomib- administered orally on predetermined days and dosage during Induction and Maintenance Phase&#xD;
Dexamethasone- administered via IV or orally on predetermined days and dosage during Induction and Maintenance Phase&#xD;
Rituximab- administered via IV on predetermined days and dosage during Induction and Maintenance Phase</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ixazomib</intervention_name>
    <description>Doses given on Days 1, 8, and 15 in induction and maintenance cycles.</description>
    <arm_group_label>IDR</arm_group_label>
    <other_name>MLN9708</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Doses given on Days 1, 8, and 15 in induction and maintenance cycles.</description>
    <arm_group_label>IDR</arm_group_label>
    <other_name>Decadron</other_name>
    <other_name>Dexasone,</other_name>
    <other_name>Diodex</other_name>
    <other_name>Hexadrol</other_name>
    <other_name>Maxidex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Doses given on Day 1 of induction and maintenance cycles.</description>
    <arm_group_label>IDR</arm_group_label>
    <other_name>Rituxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients 18 years or older.&#xD;
&#xD;
          -  Voluntary written consent must be given before performance of any study related&#xD;
             procedure not part of standard medical care, with the understanding that the patient&#xD;
             may withdraw consent at any time without prejudice to future medical care.&#xD;
&#xD;
          -  Female patients who:&#xD;
&#xD;
               -  Are postmenopausal for at least 1 year before the screening visit, OR&#xD;
&#xD;
               -  Are surgically sterile, OR&#xD;
&#xD;
               -  If they are of childbearing potential, agree to practice 2 effective methods of&#xD;
                  contraception, at the same time, from the time of signing the informed consent&#xD;
                  form through 90 days after the last dose of study drug, AND&#xD;
&#xD;
               -  Agree to practice true abstinence when this is in line with the preferred and&#xD;
                  usual lifestyle of the subject. (Periodic abstinence [eg, calendar, ovulation,&#xD;
                  symptothermal, post-ovulation methods] and withdrawal are not acceptable methods&#xD;
                  of contraception.)&#xD;
&#xD;
          -  Male patients, even if surgically sterilized (ie, status post-vasectomy), must agree&#xD;
             to one of the following:&#xD;
&#xD;
               -  Agree to practice effective barrier contraception during the entire study&#xD;
                  treatment period and through 90 days after the last dose of study drug, OR&#xD;
&#xD;
               -  Agree to practice true abstinence when this is in line with the preferred and&#xD;
                  usual lifestyle of the subject. (Periodic abstinence (eg, calendar, ovulation,&#xD;
                  symptothermal, post-ovulation methods] and withdrawal are not acceptable methods&#xD;
                  of contraception.)&#xD;
&#xD;
          -  Clinicopathological diagnosis of WM (Owen 2003), with symptomatic disease meeting&#xD;
             criteria for treatment using consensus panel criteria from the Second International&#xD;
             Workshop on WM (Kyle 2003), and measurable disease, defined as presence of&#xD;
             immunoglobulin M (IgM) paraprotein with a minimum IgM level of &gt;2 times the upper&#xD;
             limit of normal.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance status of 0, 1, or 2.&#xD;
&#xD;
          -  Patients must meet the following clinical laboratory criteria&#xD;
&#xD;
          -  Absolute neutrophil count ≥1,000/mm3 and platelet count ≥75,000/mm3. Platelet&#xD;
             transfusions to help patients meet eligibility criteria are not allowed within 3 days&#xD;
             before study enrollment.&#xD;
&#xD;
          -  Total bilirubin ≤1.5 x the upper limit of the normal range (ULN).&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3 x ULN.&#xD;
&#xD;
          -  Calculated creatinine clearance ≥30 mL/min.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female patients who are lactating or have a positive serum pregnancy test during the&#xD;
             screening period.&#xD;
&#xD;
          -  Major surgery within 14 days before enrollment.&#xD;
&#xD;
          -  Central nervous system involvement.&#xD;
&#xD;
          -  Infection requiring systemic antibiotic therapy or other serious infection within 14&#xD;
             days before study enrollment.&#xD;
&#xD;
          -  Evidence of current uncontrolled cardiovascular conditions, including uncontrolled&#xD;
             hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure,&#xD;
             unstable angina, or myocardial infarction within the past 6 months.&#xD;
&#xD;
          -  Systemic treatment, within 14 days before the first dose, with strong inhibitors of&#xD;
             cytochrome P (CYP) 1A2, strong inhibitors of CYP3A, or strong CYP3A inducers, or use&#xD;
             of Ginkgo biloba or St. John's wort.&#xD;
&#xD;
          -  Known hepatitis B or C virus, or HIV infection.&#xD;
&#xD;
          -  Any serious medical or psychiatric illness that could, in the investigator's opinion,&#xD;
             potentially interfere with the completion of treatment according to this protocol.&#xD;
&#xD;
          -  Known allergy to any of the study medications, their analogues, or excipients in the&#xD;
             various formulations of any agent.&#xD;
&#xD;
          -  Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral&#xD;
             absorption or tolerance of ixazomib including difficulty swallowing.&#xD;
&#xD;
          -  Diagnosed or treated for another malignancy within 2 years before study enrollment or&#xD;
             previously diagnosed with another malignancy and have any evidence of residual&#xD;
             disease. Patients with non-melanoma skin cancer or carcinoma in situ of any type are&#xD;
             not excluded if they have undergone complete resection.&#xD;
&#xD;
          -  Participation in other clinical trials, including those with other investigational&#xD;
             agents not included in this trial, within 30 days of the start of this trial and&#xD;
             throughout the duration of this trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jorge J. Castillo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>March 10, 2015</study_first_submitted>
  <study_first_submitted_qc>March 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2015</study_first_posted>
  <results_first_submitted>July 24, 2020</results_first_submitted>
  <results_first_submitted_qc>August 20, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 2, 2020</results_first_posted>
  <last_update_submitted>August 20, 2020</last_update_submitted>
  <last_update_submitted_qc>August 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Jorge J. Castillo, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Waldenstrom's Macroglobulinemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Ixazomib</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 13, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/37/NCT02400437/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ixazomib, Dexamethasone, Rituximab</title>
          <description>- IDR The study treatment will consist on an induction and a maintenance phase. Dose modification will be permitted for toxicity&#xD;
Induction cycles will be 4 weeks long, Maintenance cycles 8 weeks long.&#xD;
Ixazomib- administered orally on predetermined days and dosage during Induction and Maintenance Phase&#xD;
Dexamethasone- administered via IV or orally on predetermined days and dosage during Induction and Maintenance Phase&#xD;
Rituximab- administered via IV on predetermined days and dosage during Induction and Maintenance Phase&#xD;
Ixazomib: Doses given on Days 1, 8, and 15 in induction and maintenance cycles.&#xD;
Dexamethasone: Doses given on Days 1, 8, and 15 in induction and maintenance cycles.&#xD;
Rituximab: Doses given on Day 1 of induction and maintenance cycles.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants are included in the analysis.</population>
      <group_list>
        <group group_id="B1">
          <title>Ixazomib, Dexamethasone, Rituximab</title>
          <description>- IDR The study treatment will consist on an induction and a maintenance phase. Dose modification will be permitted for toxicity&#xD;
Induction cycles will be 4 weeks long, Maintenance cycles 8 weeks long.&#xD;
Ixazomib- administered orally on predetermined days and dosage during Induction and Maintenance Phase&#xD;
Dexamethasone- administered via IV or orally on predetermined days and dosage during Induction and Maintenance Phase&#xD;
Rituximab- administered via IV on predetermined days and dosage during Induction and Maintenance Phase&#xD;
Ixazomib: Doses given on Days 1, 8, and 15 in induction and maintenance cycles.&#xD;
Dexamethasone: Doses given on Days 1, 8, and 15 in induction and maintenance cycles.&#xD;
Rituximab: Doses given on Day 1 of induction and maintenance cycles.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.5" lower_limit="46" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mutational Status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>MYD88 Mutated, CXCR4 Wild-type</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>MYD88 Mutated, CXCR4 Mutated</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Very Good Partial Response Rate (VGPR) for IDR</title>
        <description>Rate of very good partial response or better in patients treated with IDR. VGPR is defined as a &gt;90% reduction in serum IgM levels from baseline.</description>
        <time_frame>76 weeks</time_frame>
        <population>All participants who have received at least 1 cycle of therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Ixazomib, Dexamethasone, Rituximab</title>
            <description>- IDR The study treatment will consist on an induction and a maintenance phase. Dose modification will be permitted for toxicity&#xD;
Induction cycles will be 4 weeks long, Maintenance cycles 8 weeks long.&#xD;
Ixazomib- administered orally on predetermined days and dosage during Induction and Maintenance Phase&#xD;
Dexamethasone- administered via IV or orally on predetermined days and dosage during Induction and Maintenance Phase&#xD;
Rituximab- administered via IV on predetermined days and dosage during Induction and Maintenance Phase&#xD;
Ixazomib: Doses given on Days 1, 8, and 15 in induction and maintenance cycles.&#xD;
Dexamethasone: Doses given on Days 1, 8, and 15 in induction and maintenance cycles.&#xD;
Rituximab: Doses given on Day 1 of induction and maintenance cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Very Good Partial Response Rate (VGPR) for IDR</title>
          <description>Rate of very good partial response or better in patients treated with IDR. VGPR is defined as a &gt;90% reduction in serum IgM levels from baseline.</description>
          <population>All participants who have received at least 1 cycle of therapy.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response Rate</title>
        <description>Overall response includes the rate of complete response (CR), partial response (PR), minimal response (MR), stabl disease (SD) and progressive disease (PD). Minor response is &gt;25%-50% reduction in serum IgM from baseline. Partial Response is (&gt;50-90% reduction in serum IgM from baseline. Very Good Partial Response is &gt;90% reduction in serum IgM from baseline. Complete Response is resolution of all symptoms, normalization of serum IgM with disappearance of IgM paraprotein, resolution of any adenopathy or splenomegaly.</description>
        <time_frame>2 Years</time_frame>
        <population>All participants who received at least 1 cycle of therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Ixazomib, Dexamethasone, Rituximab</title>
            <description>- IDR The study treatment will consist on an induction and a maintenance phase. Dose modification will be permitted for toxicity&#xD;
Induction cycles will be 4 weeks long, Maintenance cycles 8 weeks long.&#xD;
Ixazomib- administered orally on predetermined days and dosage during Induction and Maintenance Phase&#xD;
Dexamethasone- administered via IV or orally on predetermined days and dosage during Induction and Maintenance Phase&#xD;
Rituximab- administered via IV on predetermined days and dosage during Induction and Maintenance Phase&#xD;
Ixazomib: Doses given on Days 1, 8, and 15 in induction and maintenance cycles.&#xD;
Dexamethasone: Doses given on Days 1, 8, and 15 in induction and maintenance cycles.&#xD;
Rituximab: Doses given on Day 1 of induction and maintenance cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate</title>
          <description>Overall response includes the rate of complete response (CR), partial response (PR), minimal response (MR), stabl disease (SD) and progressive disease (PD). Minor response is &gt;25%-50% reduction in serum IgM from baseline. Partial Response is (&gt;50-90% reduction in serum IgM from baseline. Very Good Partial Response is &gt;90% reduction in serum IgM from baseline. Complete Response is resolution of all symptoms, normalization of serum IgM with disappearance of IgM paraprotein, resolution of any adenopathy or splenomegaly.</description>
          <population>All participants who received at least 1 cycle of therapy.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival (PFS)</title>
        <description>Duration of time from start of treatment to disease progression. Progressive disease is defined as occurring when a &gt;25% increase in serum IgM and an absolute 500mg/dL increase in IgM level occurs from the lowest attained response value, or progression of clinically significant disease related symptoms.</description>
        <time_frame>From start of treatment to time of disease progression, assessed up to 4 years after treatment start</time_frame>
        <population>All participants who received at least 1 cycle of therapy. Participants were followed for up to 2 years after treatment discontinuation.</population>
        <group_list>
          <group group_id="O1">
            <title>Ixazomib, Dexamethasone, Rituximab</title>
            <description>- IDR The study treatment will consist on an induction and a maintenance phase. Dose modification will be permitted for toxicity&#xD;
Induction cycles will be 4 weeks long, Maintenance cycles 8 weeks long.&#xD;
Ixazomib- administered orally on predetermined days and dosage during Induction and Maintenance Phase&#xD;
Dexamethasone- administered via IV or orally on predetermined days and dosage during Induction and Maintenance Phase&#xD;
Rituximab- administered via IV on predetermined days and dosage during Induction and Maintenance Phase&#xD;
Ixazomib: Doses given on Days 1, 8, and 15 in induction and maintenance cycles.&#xD;
Dexamethasone: Doses given on Days 1, 8, and 15 in induction and maintenance cycles.&#xD;
Rituximab: Doses given on Day 1 of induction and maintenance cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS)</title>
          <description>Duration of time from start of treatment to disease progression. Progressive disease is defined as occurring when a &gt;25% increase in serum IgM and an absolute 500mg/dL increase in IgM level occurs from the lowest attained response value, or progression of clinically significant disease related symptoms.</description>
          <population>All participants who received at least 1 cycle of therapy. Participants were followed for up to 2 years after treatment discontinuation.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33" lower_limit="4" upper_limit="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response Rate by MYD88 L265P and CXCR4-WHIM Status</title>
        <description>To evaluate the overall response rate of participants by MYD88 L265P and CXCR4-WHIM mutations in WM. Overall response is defined as achieving at least a minor response, or &gt;25% reduction in serum IgM from baseline.</description>
        <time_frame>2 Years</time_frame>
        <population>Number of participants who achieved a response by mutational status</population>
        <group_list>
          <group group_id="O1">
            <title>MYD88 Mutated, CXCR4 Wild-type</title>
            <description>Participants who were MYD88 mutated and did not have the CXCR4 mutation</description>
          </group>
          <group group_id="O2">
            <title>MYD88 Mutated, CXCR4 Mutated</title>
            <description>Participants with both the MYD88 mutation and a CXCR4 mutation</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate by MYD88 L265P and CXCR4-WHIM Status</title>
          <description>To evaluate the overall response rate of participants by MYD88 L265P and CXCR4-WHIM mutations in WM. Overall response is defined as achieving at least a minor response, or &gt;25% reduction in serum IgM from baseline.</description>
          <population>Number of participants who achieved a response by mutational status</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression (TTP)</title>
        <description>Duration of time from start of treatment to time of disease progression.</description>
        <time_frame>From start of treatment to time of disease progression, assessed up to 4 years after treatment start</time_frame>
        <population>All participants who received 1 cycle of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Ixazomib, Dexamethasone, Rituximab</title>
            <description>- IDR The study treatment will consist on an induction and a maintenance phase. Dose modification will be permitted for toxicity&#xD;
Induction cycles will be 4 weeks long, Maintenance cycles 8 weeks long.&#xD;
Ixazomib- administered orally on predetermined days and dosage during Induction and Maintenance Phase&#xD;
Dexamethasone- administered via IV or orally on predetermined days and dosage during Induction and Maintenance Phase&#xD;
Rituximab- administered via IV on predetermined days and dosage during Induction and Maintenance Phase&#xD;
Ixazomib: Doses given on Days 1, 8, and 15 in induction and maintenance cycles.&#xD;
Dexamethasone: Doses given on Days 1, 8, and 15 in induction and maintenance cycles.&#xD;
Rituximab: Doses given on Day 1 of induction and maintenance cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression (TTP)</title>
          <description>Duration of time from start of treatment to time of disease progression.</description>
          <population>All participants who received 1 cycle of treatment.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33" lower_limit="4" upper_limit="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response (DOR)</title>
        <description>The duration of response is measured from the time a participant achieved a response until the date of progression.</description>
        <time_frame>From the time each participant achieved a response to time of disease progression, assessed up to 4 years after treatment start</time_frame>
        <population>All participants who achieved a response to therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Ixazomib, Dexamethasone, Rituximab</title>
            <description>- IDR The study treatment will consist on an induction and a maintenance phase. Dose modification will be permitted for toxicity&#xD;
Induction cycles will be 4 weeks long, Maintenance cycles 8 weeks long.&#xD;
Ixazomib- administered orally on predetermined days and dosage during Induction and Maintenance Phase&#xD;
Dexamethasone- administered via IV or orally on predetermined days and dosage during Induction and Maintenance Phase&#xD;
Rituximab- administered via IV on predetermined days and dosage during Induction and Maintenance Phase&#xD;
Ixazomib: Doses given on Days 1, 8, and 15 in induction and maintenance cycles.&#xD;
Dexamethasone: Doses given on Days 1, 8, and 15 in induction and maintenance cycles.&#xD;
Rituximab: Doses given on Day 1 of induction and maintenance cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response (DOR)</title>
          <description>The duration of response is measured from the time a participant achieved a response until the date of progression.</description>
          <population>All participants who achieved a response to therapy.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33" lower_limit="2" upper_limit="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Next Therapy (TTNT)</title>
        <description>Duration from start of protocol treatment to time of initiation of new therapy.</description>
        <time_frame>From start of treatment until the participant begins a new therapy, assessed up to 4 years after treatment start</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ixazomib, Dexamethasone, Rituximab</title>
            <description>- IDR The study treatment will consist on an induction and a maintenance phase. Dose modification will be permitted for toxicity&#xD;
Induction cycles will be 4 weeks long, Maintenance cycles 8 weeks long.&#xD;
Ixazomib- administered orally on predetermined days and dosage during Induction and Maintenance Phase&#xD;
Dexamethasone- administered via IV or orally on predetermined days and dosage during Induction and Maintenance Phase&#xD;
Rituximab- administered via IV on predetermined days and dosage during Induction and Maintenance Phase&#xD;
Ixazomib: Doses given on Days 1, 8, and 15 in induction and maintenance cycles.&#xD;
Dexamethasone: Doses given on Days 1, 8, and 15 in induction and maintenance cycles.&#xD;
Rituximab: Doses given on Day 1 of induction and maintenance cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Next Therapy (TTNT)</title>
          <description>Duration from start of protocol treatment to time of initiation of new therapy.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39" lower_limit="4" upper_limit="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected starting after the first dose of study medication through 30 days of last treatment, an average of 1.5 years.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ixazomib, Dexamethasone, Rituximab</title>
          <description>- IDR The study treatment will consist on an induction and a maintenance phase. Dose modification will be permitted for toxicity&#xD;
Induction cycles will be 4 weeks long, Maintenance cycles 8 weeks long.&#xD;
Ixazomib- administered orally on predetermined days and dosage during Induction and Maintenance Phase&#xD;
Dexamethasone- administered via IV or orally on predetermined days and dosage during Induction and Maintenance Phase&#xD;
Rituximab- administered via IV on predetermined days and dosage during Induction and Maintenance Phase&#xD;
Ixazomib: Doses given on Days 1, 8, and 15 in induction and maintenance cycles.&#xD;
Dexamethasone: Doses given on Days 1, 8, and 15 in induction and maintenance cycles.&#xD;
Rituximab: Doses given on Day 1 of induction and maintenance cycles.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>SNOMED CT</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Heart Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Flu-like symptoms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Staph Aureus Bacteremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Renal Cell Carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Shortness of Breath</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>SNOMED CT</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Hearing loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurry vision</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Keratitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Bloating</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Rectal hemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Edema face</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Flu-like symptoms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Feeling cold</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Sweats</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Papulopustular rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Unspecified rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Iron deficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Generalized muscle weakness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Muscle weakness lower limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Muscle cramps</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Shoulder discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Foot pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Thyroid nodules</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Sinus pressure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Restless legs</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Amenorrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Rash maculopapular</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Skin ulceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jorge Castillo</name_or_title>
      <organization>Dana-Farber Cancer Institute</organization>
      <phone>617-632-2681</phone>
      <email>jorgej_castillo@dfci.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

